Pharmacokinetics and toxicity considerations for antibody–drug conjugates: an overview

Antibody–drug conjugates (ADCs) is one of the fastest-growing drug delivery systems. It involves a monoclonal antibody conjugated with payload via a ligand that directly targets the expressive protein of diseased cell. Hence, it reduces systemic exposure and provides site-specific delivery along wit...

Full description

Saved in:
Bibliographic Details
Published in:Bioanalysis 2023-10, Vol.15 (19), p.1193-1202
Main Authors: Hejmady, Siddhanth, Pradhan, Rajesh, Kumari, Shobha, Pandey, Meghna, Dubey, Sunil K, Taliyan, Rajeev
Format: Article
Language:English
Subjects:
antibody–drug conjugate
elimination
ELISA
LBA-LC–MS assays
pharmacokinetics
toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antibody–drug conjugates (ADCs) is one of the fastest-growing drug delivery systems. It involves a monoclonal antibody conjugated with payload via a ligand that directly targets the expressive protein of diseased cell. Hence, it reduces systemic exposure and provides site-specific delivery along with reduced toxicity. Because of this advantage, researchers have gained interest in this novel system. ADCs have displayed great promise in drug delivery and biomedical applications. However, a lack of understanding exists on their mechanisms of biodistribution, metabolism and side effects. To gain a better understanding of the therapeutics, careful consideration of the pharmacokinetics and toxicity needs to be undertaken. In this review, different pharmacokinetics parameters including distribution, bioanalysis and heterogeneity are discussed for developing novel therapeutics.
ISSN:1757-6180
1757-6199
DOI:10.4155/bio-2023-0104